0000000000154436

AUTHOR

Giuseppe Micali

0000-0002-5157-3939

showing 12 related works from this author

The GENDER ATTENTION Observational Study: Gender and Hormonal Status Differences in the Incidence of Adverse Events During Cyclosporine Treatment in …

2017

Introduction: Female sex has been shown to be a risk factor for the development of adverse drug reactions; however, this has not been studied for cyclosporine (CsA). The aim of this study was to investigate, in Italian dermatological practice, the influence of gender and menopause and related hormones on the incidence of adverse events (AEs) during CsA treatment in psoriatic patients. Methods: Multicenter, prospective, observational study conducted from May 2011 to June 2013. Patients with plaque psoriasis, undergoing a new CsA administration course, or about to start it, were enrolled in the outpatient clinics of Italian dermatological centers. During the 2–6 months of study duration, pati…

MaleSex FactorRate ratio030226 pharmacology & pharmacyGonadal Steroid HormoneSeverity of Illness Index0302 clinical medicineOutpatient clinicAdverse drug reaction; Cyclosporine; Dermatology; Female; Gender; PsoriasisPharmacology (medical)030212 general & internal medicineProspective StudiesProspective cohort studyGonadal Steroid HormonesOriginal ResearchIncidence (epidemiology)IncidenceMedicine (all)General MedicineMiddle AgedMenopausePostmenopauseItalyCyclosporineFemaleSettore MED/35 - MALATTIE CUTANEE E VENEREEHumanAdultmedicine.medical_specialtyAdolescentAdverse drug reaction; Cyclosporine; Dermatology; Female; Gender; Psoriasis; Adolescent; Adult; Cyclosporine; Female; Gonadal Steroid Hormones; Humans; Incidence; Italy; Male; Middle Aged; Postmenopause; Prospective Studies; Psoriasis; Severity of Illness Index; Sex Factors; Young Adult; Pharmacology (medical)Adverse drug reactionDermatology03 medical and health sciencesYoung AdultSex FactorsInternal medicineSeverity of illnessmedicineHumansPsoriasisRisk factorAdverse effectPsoriasibusiness.industryGendermedicine.diseaseSurgeryAdverse drug reaction; Cyclosporine; Dermatology; Female; Gender; Psoriasis; Medicine (all); Pharmacology (medical)Prospective StudiebusinessAdverse drug reaction; Cyclosporine; Dermatology; Female; Gender; Psoriasis;
researchProduct

Improving the disease awareness: how a communication campaign brings hidradenitis suppurativa to the light

2019

Background: Hidradenitis suppurativa is an inflammatory skin disease that presents a recurrence of painful and suppurating lesions in the apocrine gland-bearing regions, with a strong impact on the patients’ life quality. Despite its peculiar presentation, early forms are often underestimated by patients and this would inevitably result in late diagnosis and delayed therapy. Objectives: Improved communication around the disease could facilitate self-diagnosis and a quicker response from healthcare practitioners, especially in this moment when we dispose of effective treatment against this disease. Methods: A HS awareness campaign was conducted for 2 years with the help of a media agency and…

AdultMalemedicine.medical_specialtyHealth Knowledge Attitudes PracticeAdolescentdisease awarenessMEDLINEDermatologyDisease.030207 dermatology & venereal diseases03 medical and health sciencesDiagnostic Self EvaluationYoung Adult0302 clinical medicineHealth caremedicineEffective treatmentHumansHidradenitis suppurativa030212 general & internal medicineMass MediaYoung adultIntensive care medicineChildAdolescent; Adult; Aged; Child; Cysts; Diagnostic Self Evaluation; Female; Health Education; Health Knowledge Attitudes Practice; Hidradenitis Suppurativa; Humans; Male; Mass Media; Middle Aged; Social Media; Young Adult; CommunicationHealth EducationAgedPracticebusiness.industryCystsInflammatory skin diseaseHealth KnowledgeCommunicationhidradenitis suppurativadisease awareness communication hidradenitis suppurativaMiddle Agedmedicine.diseaseHidradenitis SuppurativaInfectious DiseasesCystAttitudesHealth educationFemalebusinessSettore MED/35 - MALATTIE CUTANEE E VENEREESocial MediaHuman
researchProduct

Evidence for a 'window of opportunity' in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study

2021

BACKGROUND The anti-tumour necrosis factor (TNF)-α adalimumab is the only licenced biologic for moderate-to-severe hidradenitis suppurativa (HS). No predictors of response have been identified so far. OBJECTIVES To identify clinical parameters predicting response to adalimumab and confirm its efficacy/safety. METHODS The data of 389 patients with HS treated with adalimumab in 21 Italian centres were reviewed. Sex, age at onset/diagnosis/baseline, body mass index, smoking, phenotype, previous treatments, concomitant antibiotics and 'therapeutic delay', defined as the time from HS onset to adalimumab initiation, were assessed. Response to adalimumab and its impact on quality of life (QoL) wer…

medicine.medical_specialtyVisual analogue scaleAnti-Inflammatory AgentsDermatologySeverity of Illness Index030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineSettore MED/35Quality of lifeInternal medicineSeverity of illnessmedicineAdalimumabHumansHidradenitis suppurativahidrosadenitis suppurativaRetrospective Studiesbusiness.industryAdalimumabRetrospective cohort studyOdds ratioDermatology Life Quality Indexmedicine.diseasehumanitiesHidradenitis SuppurativaTreatment OutcomeQuality of LifeAdalimumab Hidradenitis Suppurativa quality of lifeSettore MED/35 - MALATTIE CUTANEE E VENEREEbusinessmedicine.drug
researchProduct

Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry

2021

Abstract Background Few and small studies have described the management of immunomodulant/immunosuppressive therapies or phototherapy in atopic dermatitis (AD) patients during coronavirus disease 2019 (COVID‐19) pandemic. Methods A national registry, named DA‐COVID‐19 and involving 35 Italian dermatology units, was established in order to evaluate the impact of COVID‐19 pandemic on the management of adult AD patients treated with systemic immunomodulant/immunosuppressive medications or phototherapy. Demographic and clinical data were obtained at different timepoints by teledermatology during COVID‐19 pandemic, when regular visits were not allowed due to sanitary restrictions. Disease severi…

Registrie0301 basic medicineDermatitisSystemic therapy0302 clinical medicinePandemicImmunology and AllergyMedicineRegistriesatopic dermatitis; COVID; SARS‐ CoVCOVIDtreatmentatopic dermatitisatopic dermatitis; COVID; SARS-CoVSARS-CoVAtopic dermatitisDupilumabSARS‐ CoVItalyOriginal ArticleSettore MED/35 - MALATTIE CUTANEE E VENEREEHumanatopic dermatitiAdultmedicine.medical_specialtyTeledermatologyCOVID; SARS‐CoV; atopic dermatitis treatmentCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ImmunologyCOVID; SARS‐CoV; atopic dermatitis; Adult; Communicable Disease Control; Humans; Italy; Pandemics; Registries; SARS-CoV-2; COVID-19; Dermatitis AtopicAtopicDermatitis Atopic03 medical and health sciencesSettore MED/35Disease severityInternal medicineatopic dermatitis treatmentHumansPandemicsPandemicbusiness.industrySARS-CoV-2SARS‐CoVCOVID-19medicine.disease030104 developmental biology030228 respiratory systemCommunicable Disease Controlatopic dermatitis; COVID; SARS-CoV; Adult; Communicable Disease Control; Humans; Italy; Pandemics; Registries; SARS-CoV-2; COVID-19; Dermatitis Atopicatopic dermatitis COVID SARS-CoVbusiness
researchProduct

Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab The…

2022

N/A

Dupilumab TherapyAntibodies Monoclonal Humanized; Disease Progression; Humans; Treatment Outcome; COVID-19; Dermatitis AtopicDermatitisAtopic dermatitis.DermatologyDupilumabAntibodies Monoclonal HumanizedAntibodiesAtopicDermatitis AtopicSettore MED/35MonoclonalImmunology and AllergyHumanshumanHumanizedAtopic dermatitistreatment outcome Antibodies Monoclonal HumanizedCOVID-19Treatment OutcomeCOVID-19 Dupilumab Therapydisease exacerbationDisease ProgressionSettore MED/35 - MALATTIE CUTANEE E VENEREEHumanmonoclonal antibody atopic dermatiti
researchProduct

Retinal Vascular Assessment in Psoriasis: A Multicenter Study

2021

PurposeTo investigate the vascular status of the macula in psoriasis patients without history of ocular inflammation by Optical Coherence Tomography Angiography (OCTA).MethodsThis prospective cross-sectional multicenter study included 55 psoriasis patients and 55 control healthy subjects. A complete eye examination and 6 mm × 6 mm OCTA imaging were performed. Retinal vascular status was evaluated by analyzing vascular density (VD) of superficial vascular plexus (superficial wVD) and deep vascular plexuses (deep wVD) in a 6 mm × 6 mm area and in foveal (superficial fVD and deep fVD) and parafoveal sectors (superficial pVD and deep pVD). In addition, foveal thickness (FT) and foveal avascular…

retinaIntraocular pressuremedicine.medical_specialtyvascular changesgenetic structuresmacula; optical coherence tomography angiography; psoriasis; retina; vascular changesoptical coherence tomography angiographylcsh:RC321-571030207 dermatology & venereal diseases03 medical and health scienceschemistry.chemical_compoundPsoriatic arthritis0302 clinical medicineOphthalmologyPsoriasisMedicinemaculalcsh:Neurosciences. Biological psychiatry. NeuropsychiatrypsoriasiOriginal ResearchRetinamedicine.diagnostic_testbusiness.industryGeneral NeuroscienceRetinalpsoriasisOptical coherence tomography angiographymedicine.diseaseeye diseasesmedicine.anatomical_structurechemistryMulticenter studyEye examination030221 ophthalmology & optometrysense organsbusinessNeuroscienceFrontiers in Neuroscience
researchProduct

Prevalence and risk factors of actinic keratosis in patients attending Italian dermatology clinics

2017

Background: Actinic keratosis (AK) is a common keratinocyte intraepidermal neoplasia. Objective: To assess AK prevalence and potential risk factors in patients attending Italian general dermatology clinics. Materials & methods: This retrospective study was conducted on clinical data from consecutive white outpatients aged ≥30 years, attending 24 general dermatology clinics between December 2014 and February 2015. AK prevalence (entire population) and multivariate risk factor analysis (patients with current/previous AK and complete data) are presented. Results: AK prevalence in 7,284 patients was 27.4% (95% CI: 26.4-28.4%); 34.3% in men and 20.0% in women (p<0.001). Independent AK ris…

Complete datamedicine.medical_specialtySkin typeskin neoplasmseuropean continental ancestry groupWhite People030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicinemaleRetrospective Studiemiddle agedmedicinePrevalenceIn patientSkin NeoplasmRisk factorhumansMale genderEntire populationbusiness.industryActinic keratosiRisk FactoradultActinic keratosisambulatory care facilitiesRetrospective cohort studymedicine.diseaseDermatologyAmbulatory Care FacilitieKeratosis Actinicdermatologyagedretrospective studiesactinic keratosis; Italy; prevalence; risk factors; adult; aged; ambulatory care facilities; dermatology; european continental ancestry group; female; humans; keratosis actinic; male; middle aged; prevalence; retrospective studies; risk factors; skin neoplasmsfemaleItalyRisk factors030220 oncology & carcinogenesisActinic keratosis; Italy; Prevalence; Risk factorskeratosisActinic keratosis; Italy; Prevalence; Risk factors; 2708actinicActinic keratosisbusinessSettore MED/35 - MALATTIE CUTANEE E VENEREEHuman2708
researchProduct

Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic. risk analysis from the PSO-BIO-COVI…

2021

Background The susceptibility of patients with chronic plaque psoriasis and the risks or benefits related to the use of biological therapies for COVID-19 are unknown. Few data about prevalence, clinical course and outcomes of COVID-19 among psoriatic patients were reported. The aims of this study were 1) to assess the prevalence and severity of COVID-19 in psoriatic patients treated with biologic agents during the first phase of the emergency (22 February to 22 April 2020) in Italy, and 2) to report the clinical outcomes of patients who have been exposed to individuals with confirmed SARS-CoV-2 infection. Methods Patients with moderate-to-severe chronic plaque psoriasis, aged ≥18 years and …

0301 basic medicineMaleClinical BiochemistryDiseaseCohort Studies0302 clinical medicineDrug DiscoveryReceptors80 and overMedicineAged 80 and overeducation.field_of_studyIncidence (epidemiology)IncidenceInterleukin-17psoriasisMiddle Ageddermatologysars-CoV-2Italybiological therapy030220 oncology & carcinogenesisCohortBiological ProductCOVID-19; biological therapy; dermatology; psoriasis; sars-CoV-2FemaleSettore MED/35 - MALATTIE CUTANEE E VENEREEbiological therapy; COVID-19; dermatology; psoriasis; sars-CoV-2; Adult; Aged; Aged 80 and over; Biological Products; Biological Therapy; COVID-19; Chronic Disease; Cohort Studies; Female; Humans; Incidence; Interleukin-17; Italy; Male; Middle Aged; Pandemics; Psoriasis; Receptors Interleukin; Risk Assessment; Tumor Necrosis Factor-alpha; Young AdultCohort studyHumanAdultmedicine.medical_specialtyPopulationRisk AssessmentCOVID-19; psoriasis; biological therapy; dermatology; sars-CoV-203 medical and health sciencesYoung AdultSettore MED/35Internal medicinePsoriasisPsoriasis.HumanseducationPandemicsAgedPharmacologyPsoriasiBiological ProductsPandemicbiological therapy; COVID-19; dermatology; psoriasis; sars-CoV-2business.industryTumor Necrosis Factor-alphaCOVID-19Receptors InterleukinBiological productInterleukinmedicine.diseaseClinical trial030104 developmental biologyChronic DiseaseCOVID-19; SARS-CoV-2; biological therapy; dermatology; psoriasisCohort Studiebusiness
researchProduct

Age and gender influence on HIDRAdisk outcomes in adalimumab-treated hidradenitis suppurativa patients.

2019

Background: Hidradenitis suppurativa (HS) is a chronic relapsing inflammatory skin disease characterized by a significant impairment of patients’ quality of life (QoL). It has been recently found that clinical severity of HS does not correlate well with QoL. Therefore, it is important to enhance the evaluation of severity considering the disease burden on QoL. Recently, a new graphical tool able to better describe HS burden, the so-called HIDRAdisk, has been introduced. Objective: To investigate the utility of HIDRAdisk in clinical practice before and after treatment and to analyse whether specific factors such as age and gender may influence the outcomes in patients with moderate-to-severe…

AdultMalemedicine.medical_specialtyVisual Analog ScaleDermatology.Severity of Illness IndexAge and gender030207 dermatology & venereal diseases03 medical and health sciencesYoung Adult0302 clinical medicineSex FactorsDisease severityQuality of lifeHidradenitis suppurativa quality of lifeCost of IllnessInternal medicinemedicineAdalimumabHumansIn patientHidradenitis suppurativa030212 general & internal medicineDisease burdenRetrospective Studiesbusiness.industryAge FactorsRetrospective cohort studyMiddle Agedmedicine.diseaseHidradenitis SuppurativaInfectious DiseasesTreatment OutcomeQuality of LifeFemalebusinessSettore MED/35 - MALATTIE CUTANEE E VENEREEHIDRAdisk outcomesmedicine.drughidradiskJournal of the European Academy of Dermatology and Venereology : JEADVReferences
researchProduct

Update on the Management of Pediatric Psoriasis: An Italian Consensus

2022

Introduction Psoriasis affects children with a considerable burden in early life. Treating pediatric psoriasis is challenging also because of the lack of updated specific guidelines. With the recent approval of several biologics for pediatric psoriasis and the ongoing COVID-19 pandemic, the management of young psoriatic patients is facing major changes. A revision of treatment recommendations is therefore needed. Methods In September 2021, a board of six Italian dermatologists convened to update treatment recommendations. The board issued evidence- and consensus-based statements covering relevant areas of pediatric psoriasis, namely: assessment of psoriasis severity, management of children …

Topical corticosteroidsAdolescentBiologicSystemic therapyCorticosteroid-sparingHealth-related quality of lifePediatric psoriasisDermatologyBiologicsAdolescentsPlaque psoriasiAdolescents; Biologics; Children; Corticosteroid-sparing; Health-related quality of life; Pediatric psoriasis; Plaque psoriasis; Systemic therapy; Topical corticosteroidsSettore MED/35Pediatric psoriasiPlaque psoriasisSettore MED/35 - MALATTIE CUTANEE E VENEREEChildren
researchProduct

Italian Euromelanoma Day Screening Campaign (2005-2007) and the planning of melanoma screening strategies.

2011

Although no study has definitively shown that unfocused screening of skin cancer is effective, many campaigns have been organized with the aim of increasing awareness on melanoma risk factors. The objective of this study was to analyse the results of the Skin Cancer Screening Day in Italy during the period 2005-2007, to determine the priorities for melanoma control plans in a Mediterranean country. A total of 5002 patients were screened by dermatologists in 31 cities. Individuals who considered themselves to have many naevi and those with a family history of melanoma showed a higher number of common and atypical naevi. Ten melanomas, 20 basal cell carcinomas and two squamous cell carcinomas…

Program evaluationMaleCancer ResearchSkin NeoplasmsTime FactorsEpidemiologyBasal CellpreventionRisk Factorsself-surveillance80 and overSettore MED/35 - Malattie Cutanee E VenereeMedicineMass Screeningmelanoma screening campaignMelanoma prevention strategy Melanoma risk factors Melanoma screening campaign Self-surveillance Skin cancerFamily historyYoung adultChildMelanomaAged 80 and overeducation.field_of_studyNevus Pigmentedskin cancerMelanomaMiddle AgedMALIGNANT MELANOMA; screeningPrognosisOncologyItalymelanoma; screening; risk factors; prevention; prognosisChild PreschoolCarcinoma Squamous CellFemaleAdultmedicine.medical_specialtyAdolescentPopulationmelanoma prevention strategy; melanoma risk factors; melanoma screening campaign; self-surveillance; skin cancermelanoma prevention strategyYoung AdultPigmentedHumansmelanoma prevention strategy; melanoma risk factors; melanoma screening campaign; skin cancer; self-surveillancePreschooleducationNevusSocioeconomic statusMass screeningAgedbusiness.industrymelanoma risk factorsscreeningCarcinomaPublic Health Environmental and Occupational Healthmelanoma risk factorInfantmedicine.diseaseDermatologyMALIGNANT MELANOMASquamous CellCarcinoma Basal CellSelf-ExaminationSkin cancerbusinessProgram Evaluation
researchProduct

Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy

2020

The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, is creating an unprecedented global public health emergency with the continuous growth of infected individuals worldwide. Italy was one of the first European country to face the first wave of infection outside mainland China. The first case of COVID-19 was confirmed in Lombardy on February 20th , 2020, and subsequently, a rapid increase in the number of detected cases was observed, spreading through Italy and the rest of Europe.3 As of April 22nd , confirmed COVID-19 cases in Italy were 183,957.

medicine.medical_specialtyTildrakizumabBiolgical therapy; COVID-19; PsoriasisSettore MED/35PsoriasisChronic Disease; Emergencies; Humans; Italy; Psoriasis; Biological Therapy; COVID-19UstekinumabmedicineAdalimumabHumansPsoriasisbiologicsIntensive care medicineLetter to the Editorpsoriasipsoriasis; biologics; covid-19; pandemicEmergenciePsoriasiRisankizumabbusiness.industrySARS-CoV-2pandemicBiolgical therapyCOVID-19medicine.diseasedermatologyBiological TherapyIxekizumabGuselkumabInfectious Diseasescovid-19ItalyChronic DiseaseSecukinumabEmergenciesbusinessSettore MED/35 - MALATTIE CUTANEE E VENEREEbiologicCOVID-19 psoriasis biological therapiesmedicine.drugHuman
researchProduct